Department of Nuclear Medicine (F.A.V., C.R., H.H.), and Comprehensive Cancer Center Mainfranken (U.M.), University of Wuerzburg, 97080 Wuerzburg, Germany; and Department of Nuclear Medicine (F.A.V.), RWTH University Hospital Aachen, 52074 Aachen, Germany.
J Clin Endocrinol Metab. 2014 Dec;99(12):4487-96. doi: 10.1210/jc.2014-1631.
Recent trial results have revived interest in low-activity initial (131)I therapy (RIT) of differentiated thyroid cancer (DTC).
This study sought to compare different initial (131)I activities for outcome.
A database study was performed in a University hospital.
1298 DTC patients were included (698 low risk, 434 high risk M0, and 136 M1), grouped according to ablation activity (I, ≤ 2000 MBq [54 mCi]; II, 2000-3000 MBq [54-81 mCi]; and III, >3000 MBq [81 mCi]), subdivided by age (<45 and ≥ 45 y at diagnosis).
Complete remission (CR, defined as thyroglobulin [Tg] below functional sensitivity combined with visually negative (131)I diagnostic whole-body scintigraphy), recurrence, DTC-specific mortality, and relative survival rates were studied.
Low-risk patients: In patients <45 years, a lower median cumulative activity was required to achieve CR in group III (3590 MBq) than in groups I (8050 MBq) and II (6300 MBq). In patients at least 45 years of age, DTC-specific mortality was significantly higher in group I than in groups II and III (15-y: 16.1 ± 7.7%, 0.8 ± 0.8%, and 7.2 ± 5.5%, respectively; P = .004). High-risk M0 patients: In patients at least 45 years of age, the recurrence rate (15-y: 44.4 ± 16.6%, 24.1 ± 7.6%, and 8.6 ± 3.9%; P = .001) and DTC-specific mortality (15-y: 51.8 ± 15.8%, 13.2 ± 4.4%, and 9.5 ± 3.7%; P = .004) were significantly higher in group I than in groups II and III. M1 patients: There were no significant differences in survival results between different activity groups in either age category.
Before adopting low initial activity RIT for, especially older, low-risk patients, results of long-term followup should be regarded critically. Low-activity RIT in older, high-risk patients is not to be recommended.
最近的临床试验结果重新燃起了人们对分化型甲状腺癌(DTC)低活性初始(131)I 治疗(RIT)的兴趣。
本研究旨在比较不同初始(131)I 活性对结局的影响。
在一所大学医院进行了数据库研究。
纳入 1298 例 DTC 患者(698 例低危、434 例高危 M0 和 136 例 M1),根据消融活性(I:≤2000MBq[54mCi];II:2000-3000MBq[54-81mCi];III:>3000MBq[81mCi])分组,并按年龄(<45 岁和≥45 岁)进一步细分。
完全缓解(CR,定义为甲状腺球蛋白[Tg]低于功能敏感性,同时 131I 诊断全身闪烁扫描阴性)、复发、DTC 特异性死亡率和相对生存率。
低危患者:在<45 岁的患者中,III 组(3590MBq)获得 CR 所需的中位累积活性明显低于 I 组(8050MBq)和 II 组(6300MBq)。在至少 45 岁的患者中,I 组的 DTC 特异性死亡率明显高于 II 组和 III 组(15 年:16.1±7.7%、0.8±0.8%和 7.2±5.5%;P=0.004)。高危 M0 患者:在至少 45 岁的患者中,I 组的复发率(15 年:44.4±16.6%、24.1±7.6%和 8.6±3.9%;P=0.001)和 DTC 特异性死亡率(15 年:51.8±15.8%、13.2±4.4%和 9.5±3.7%;P=0.004)明显高于 II 组和 III 组。M1 患者:在两个年龄组中,不同活性组之间的生存结果无显著差异。
在为,特别是年龄较大的低危患者采用低初始活性 RIT 之前,应谨慎考虑长期随访结果。不建议对年龄较大的高危患者采用低活性 RIT。